Improving the American Drug Supply Chain Act of 2020
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Oct 13, 2020)
Improving the American Drug Supply Chain Act of 2020
This bill requires the Department of Health and Human Services to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine to (1) study the current and historical production of drugs and key ingredients in the United States and in foreign countries, and (2) formulate recommendations for promoting increased production of drugs and key ingredients in the United States.
What just happenedOct 13, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Who’s behind it
- Introduced in HouseOct 13, 2020
- Oct 13, 2020IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Foreign Affairs Committee - Oct 13, 2020IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Oct 13, 2020IntroReferralIntro-H
Introduced in House
- Oct 13, 2020IntroReferral1000
Introduced in House